Exerkine Corporation develops novel exosome-based therapies for genetic and aging-related diseases. Focusing on improving patient outcomes, their therapies show superior efficacy in treating genetic disorders like lysosomal storage diseases, mitochondrial and neuromuscular diseases, and cystic fibrosis. Exerkine’s protein therapies also target aging-related conditions, including muscle atrophy, obesity, and type 2 diabetes, surpassing existing treatments in both molecular and clinical outcomes.